Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New data highlighting potential for monthly drug dosing

Novozymes Biopharma UK : 29 January, 2014  (Technical Article)
Data set presented at PepTalk 2014 demonstrate technological advances for extending serum half-life of drugs bound to albumin
New data highlighting potential for monthly drug dosing


Novozymes Biopharma has announced new data on extending the serum half-life of albumin in vivo. This compelling data set, recently presented at PepTalk 2014, demonstrates the potential of the company's half-life extension platform to deliver greater control of the therapeutic half-life of drug candidates, while showing how the technology can introduce the possibility for monthly dosing.



"This data represents the most promising insight yet that Novozymes' half-life extension technology delivers the reduction in dosing frequency that we set out to deliver when we began developing the platform five years ago," comments Dermot Pearson, Marketing Director at Novozymes Biopharma. He continues, "The level of excitement expressed by our customers in response to these achievements has been exceptional and we look forward to sharing our latest findings with wider industry experts who can benefit from this leading-edge data."



Through the modification of the human albumin molecule, Novozymes has altered the affinity of albumin to the FcRn receptor and has been able to demonstrate extended serum half-life of a range of albumin variants in vivo. The innovative technology provides drug developers with an attractive approach for optimizing the serum half-life of biopharmaceuticals. Already demonstrated in the fields of diabetes, hemophilia and neutropenia, the platform offers the potential to enhance patient quality of life through tailoring drug circulatory half-life to meet specific medical needs, while contributing improvements in compliance and healthcare costs.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo